The combination of two bronchodilators with different mechanisms of action to treat patients with chronic obstructive pulmonary disease (COPD) is an established medical practice, but the dissimilarities in the onset and duration of action of long-acting β2-agonists (LABA) and long-acting muscarinic agents (LAMA) and differences in the devices used for the delivery of these drugs make free combinations uncomfortable and unpredictable, especially if focused on adherence to prescribed treatment. Therefore, there is the need for fixed-dose combinations (FDCs) of bronchodilators in a single inhaler.
Matera, M., Rogliani, P., Cazzola, M. (2015). QVA149 (indacaterol/glycopyrronium) for the treatment of chronic obstructive pulmonary disease. EXPERT OPINION ON PHARMACOTHERAPY, 16(7), 1079-1090 [10.1517/14656566.2015.1032247].
QVA149 (indacaterol/glycopyrronium) for the treatment of chronic obstructive pulmonary disease
ROGLIANI, PAOLA;CAZZOLA, MARIO
2015-01-01
Abstract
The combination of two bronchodilators with different mechanisms of action to treat patients with chronic obstructive pulmonary disease (COPD) is an established medical practice, but the dissimilarities in the onset and duration of action of long-acting β2-agonists (LABA) and long-acting muscarinic agents (LAMA) and differences in the devices used for the delivery of these drugs make free combinations uncomfortable and unpredictable, especially if focused on adherence to prescribed treatment. Therefore, there is the need for fixed-dose combinations (FDCs) of bronchodilators in a single inhaler.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
